Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 8/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30290030 | 1.00 | F12 (0.36) | F12BCHEALDH1A1MEN1GAA | |
| SCHEMBL2172550 | 1.00 | F12 (0.36) | F12BCHEALDH1A1MEN1GAA | |
| SCHEMBL2172225 | 1.00 | F12 (0.36) | F12BCHEALDH1A1MEN1GAA | |
| Hydrochloric Acid SCHEMBL27979283 | 0.98 | ALDH1A1 (0.37) | F12BCHEALDH1A1MEN1GAA | |
| Ethane SCHEMBL11061598 | 0.96 | BCHE (0.36) | F12BCHEHTR2C | |
| SCHEMBL1652868 | 0.88 | BCHE (0.34) | F12BCHEALDH1A1MEN1GAA | |
| SCHEMBL793625 | 0.78 | CHRNB4 (0.37) | ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL29636531 | 0.78 | CHRNB4 (0.37) | ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL8703745 | 0.78 | CHRNB4 (0.37) | ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL12350365 | 0.75 | HTR2C (0.39) | F12BCHEALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116376858-A | Application of monoamine oxidase from microorganism as catalyst in preparation of quinoline or quinoline derivative | 浙江大学杭州国际科创中心 | 2023-07-04 | — | — | CN | claimed |
| CN-112745295-A | Acetamide compound and preparation method and application thereof | 张惠娜 | 2021-05-04 | — | — | CN | claimed |
| EP-1964925-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-1,2,3,4 -TETRAHYDROQUINOLINES | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-03-30 | — | — | EP | claimed |
| CN-104163797-A | Synthetic method of 4-hydroxy-1,2,3,4-tetrahydroquinoline | UNIV ZUNYI MEDICAL | 2014-11-26 | — | — | CN | claimed |
| WO-2013157018-A1 | A PROCESS FOR THE PREPARATION OF THE CORE STRUCTURE IN QUINOLONE AND NAPTHYRIDONE CLASS OF ANTIBIOTICS | INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IN) | 2013-10-24 | — | — | WO | claimed |
| US-7972836-B2 | Method of enzymatic optical resolution of racemic 4-hydroxy-1,2,3,4-tetrahydroquinoline | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | claimed |
| US-20090269821-A1 | Method for Preparing Optically Active 4-Hydroxy-1,2,3,4-Tetrahydroquinoline Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-29 | — | — | US | claimed |
| EP-1964925-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-1,2,3,4 -TETRAHYDROQUINOLINES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-03 | — | — | EP | claimed |
| US-3992386-A | 4(Quinolyl)phenoxy alkanoic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-11-16 | — | — | US | claimed |
| EP-4041727-B1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| WO-1985000602-A1 | DI/TETRA-HYDROQUINOLINES | BEECHAM GROUP P.L.C. (GB) | 1985-02-14 | — | — | WO | disclosed |
| US-4053626-A | CHOLESTEROL LEVEL-LOWERING PHENOXYACETIC ACIDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-10-11 | — | — | US | disclosed |
| US-4053626-A | CHOLESTEROL LEVEL-LOWERING PHENOXYACETIC ACIDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-10-11 | — | — | US | disclosed |
| US-4051170-A | Diphenoxyacetic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-09-27 | — | — | US | disclosed |
| US-3992386-A | 4(Quinolyl)phenoxy alkanoic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3992386-A | 4(Quinolyl)phenoxy alkanoic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | F12 2390/4885BCHE 3940/4885ALDH1A1 2918/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | F12 2390/4885BCHE 3940/4885ALDH1A1 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.